CEL-SCI (CVM) Stock Price

CEL-SCI Price

NYSE AMEX·CLOSED
2.08
​
Market closed

Over the last 14 years CEL-SCI grew revenue by 11.3% annually, reaching 558,664.00 USD. For CEL-SCI, the net margin of -5,419.5% is down versus -4,022.6% a few years ago. The consensus 12-month price target for CEL-SCI is 6.32 USD, about 204.0% above where the stock trades today. Of 6 analysts, 5 rate the stock a buy — an overall Buy consensus.

CEL-SCI stock price

Access this data via the Eulerpool API

CEL-SCI business model & stock analysis

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia and currently employs 43 full-time employees. The firm is focused on activating the immune system to fight cancer and infectious diseases. The company operates through the segment of research and development of certain drugs and vaccines. The company is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

Frequently asked questions about CEL-SCI

Analysts currently set an average price target of 7.55 USD for the CEL-SCI stock (median: 6.32 USD), implying +262.9 % versus the latest price. The consensus is based on 6 analyst ratings.

5 analysts currently rate the CEL-SCI stock: 4 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the CEL-SCI share trades at 1.85 EUR (2.08 USD).

The CEL-SCI share (CVM) is listed on 4 stock exchanges, including: Frankfurt (LSRM.F), München (LSRM.MU), Düsseldorf (LSRM.DU).

The revenue cannot currently be calculated for CEL-SCI.

The expected profit of CEL-SCI is -4.55 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of CEL-SCI is currently -3.66. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CEL-SCI stock.

The P/S cannot be calculated for CEL-SCI currently.

The Eulerpool Quality Score for CEL-SCI is 2/10.

The ISIN of CEL-SCI is US1508377066. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of CEL-SCI is A2DY0D. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of CEL-SCI is CVM. The ticker symbol is used to trade CEL-SCI shares on the stock exchange.

Fair ValueTerminal
1.85 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website cel-sci.com
Currency
USD
Initial public offering
Dec 8, 1983
ISIN
US1508377066
Cusip
150837607
Sedol
BDFZC26
Market capitalization
3.08 M USDMicro Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee 2026
-3.66
P/Ee 2027
-1.76
P/Ee 2028
2.51
P/S
P/Se
—
EV/EBIT
0.38
P/B Ratio
0.19
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-100.28 %
Gross Margin
—
EBIT Margin
—
Net Margin
—
EPS (Earnings Per Share)
-3.17 USD
Net Debt / EBIT
0.51
Debt/Equity
0.59
Last updated Oct 5, 2026, 10:24 AM

CEL-SCI Ticker

AMEX · CVMDÜSSELDORF · LSRM.DUFRANKFURT · LSRM.FMUNICH · LSRM.MU

All fundamentals and in-depth analysis of CEL-SCI

Our stock analysis for CEL-SCI stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CEL-SCI. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.